Last reviewed · How we verify
placebo + PEGinterferon alfa-2a
placebo + PEGinterferon alfa-2a is a Interferon alfa Small molecule drug developed by SciClone Pharmaceuticals. It is currently in Phase 3 development for Chronic hepatitis C (in combination with ribavirin), Chronic hepatitis B.
PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways.
PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways. Used for Chronic hepatitis C (in combination with ribavirin), Chronic hepatitis B.
At a glance
| Generic name | placebo + PEGinterferon alfa-2a |
|---|---|
| Sponsor | SciClone Pharmaceuticals |
| Drug class | Interferon alfa |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PEGinterferon alfa-2a is a pegylated form of interferon alfa-2a that binds to interferon-alpha receptors on immune cells and hepatocytes, triggering JAK-STAT signaling and upregulation of interferon-stimulated genes. This leads to enhanced natural killer cell activity, increased MHC expression, and direct antiviral effects. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to standard interferon alfa-2a.
Approved indications
- Chronic hepatitis C (in combination with ribavirin)
- Chronic hepatitis B
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/psychiatric effects
- Thyroid dysfunction
- Injection site reactions
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (PHASE1)
- A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
- Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression (PHASE2)
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (PHASE3)
- Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients (PHASE2)
- A Study in Healthy Volunteers and Patients With Chronic Hepatitis B (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo + PEGinterferon alfa-2a CI brief — competitive landscape report
- placebo + PEGinterferon alfa-2a updates RSS · CI watch RSS
- SciClone Pharmaceuticals portfolio CI
Frequently asked questions about placebo + PEGinterferon alfa-2a
What is placebo + PEGinterferon alfa-2a?
How does placebo + PEGinterferon alfa-2a work?
What is placebo + PEGinterferon alfa-2a used for?
Who makes placebo + PEGinterferon alfa-2a?
What drug class is placebo + PEGinterferon alfa-2a in?
What development phase is placebo + PEGinterferon alfa-2a in?
What are the side effects of placebo + PEGinterferon alfa-2a?
What does placebo + PEGinterferon alfa-2a target?
Related
- Drug class: All Interferon alfa drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR)
- Manufacturer: SciClone Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Chronic hepatitis C (in combination with ribavirin)
- Indication: Drugs for Chronic hepatitis B
- Compare: placebo + PEGinterferon alfa-2a vs similar drugs
- Pricing: placebo + PEGinterferon alfa-2a cost, discount & access